PE20061013A1 - Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias - Google Patents

Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias

Info

Publication number
PE20061013A1
PE20061013A1 PE2006000220A PE2006000220A PE20061013A1 PE 20061013 A1 PE20061013 A1 PE 20061013A1 PE 2006000220 A PE2006000220 A PE 2006000220A PE 2006000220 A PE2006000220 A PE 2006000220A PE 20061013 A1 PE20061013 A1 PE 20061013A1
Authority
PE
Peru
Prior art keywords
methyl
ethyl
quinoline
trans
phenyl
Prior art date
Application number
PE2006000220A
Other languages
English (en)
Inventor
Jeremy D Little
Shomir Ghosh
Amy M Elder
Kenneth G Carson
Christelle C Renou
Sean J Harrison
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36593677&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061013(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20061013A1 publication Critical patent/PE20061013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES UN ANILLO ARILO O HETEROARILO DE 5-6 MIEMBROS CONDENSADO; Y ES DE PREFERENCIA CH; X1 ES DE PREFERENCIA -CO-; R1 ES 4-METOXIFENIL, PIRIMIDINA, 4-TRIFLUOROMETILFENIL, 3-METIL-ISOXAZOL, ENTRE OTROS; R2 ES ALQUILO C1-C3, HALOALQUILO C1-C3, CICLOALQUILO C1-C3, ENTRE OTROS; R3 ES H, ALQUILO C1-C6 SUSTITUIDO O NO, FLUOROALQUILO C1-C6, CICLOALQUILO C3-C8 SUSTITUIDO O NO, ENTRE OTROS; R4 ES ETILO, METILO, H, ISOPROPIL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ETIL-(4-TRIFLUOROMETIL-FENIL)-AMIDA DEL ACIDO TRANS-1-(4-METOXI-BENZOIL)-2-METIL-1,2,3,4-TETRAHIDRO-QUINOLINA-4-QUINOLINA; ESTER ETILICO DEL ACIDO TRANS-4-(4-{4-[(4-CLORO-FENIL)-ETIL-CARBAMOIL]-2-METIL-3,4-DIHIDRO-2H-QUINOLINA-1-CARBONIL}-FENOXI)-BUTIRICO; ETIL-4-(4-NITRO-FENIL)-AMIDA DEL ACIDO TRANS-1-(4-METOXI-BENZOIL)-2-METIL-1,2,3,4-TETRAHIDRO-QUINOLINA-4-CARBOXILICO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CRTH2 UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y/O TRASTORNOS CON UN COMPONENTE INFLAMATORIO
PE2006000220A 2005-02-24 2006-02-24 Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias PE20061013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65592705P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
PE20061013A1 true PE20061013A1 (es) 2006-10-13

Family

ID=36593677

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000220A PE20061013A1 (es) 2005-02-24 2006-02-24 Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias

Country Status (26)

Country Link
US (1) US7951950B2 (es)
EP (1) EP1861372A1 (es)
JP (1) JP2008543726A (es)
KR (1) KR20070114762A (es)
CN (1) CN101146776A (es)
AR (1) AR052580A1 (es)
AU (1) AU2006216713A1 (es)
BR (1) BRPI0608553A2 (es)
CA (1) CA2598133A1 (es)
CR (1) CR9378A (es)
DO (1) DOP2006000054A (es)
GT (1) GT200600093A (es)
IL (1) IL185422A0 (es)
MA (1) MA29330B1 (es)
MX (1) MX2007010215A (es)
NI (1) NI200700221A (es)
NO (1) NO20074388L (es)
PE (1) PE20061013A1 (es)
RU (1) RU2007135224A (es)
SV (1) SV2007002429A (es)
TN (1) TNSN07325A1 (es)
TW (1) TW200640869A (es)
UA (1) UA90706C2 (es)
UY (1) UY29397A1 (es)
WO (1) WO2006091674A1 (es)
ZA (1) ZA200707498B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITVA20050050A1 (it) * 2005-08-05 2007-02-06 Lamberti Spa Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita'
US20100015085A1 (en) * 2006-05-01 2010-01-21 Johns Hopkins University Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress
EP2229358B1 (en) 2007-12-14 2011-03-23 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
US8124641B2 (en) 2008-07-15 2012-02-28 Hoffmann-La Roche Inc. Aminotetrahydroindazoloacetic acids
EP2307383B1 (en) 2008-07-15 2012-05-16 F. Hoffmann-La Roche AG Aminotetrahydroindazoloacetic acids
WO2010018109A2 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Substituted aminotetralines
CA2735392A1 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
JP5463365B2 (ja) 2008-11-17 2014-04-09 エフ．ホフマン−ラ ロシュ アーゲー ナフチル酢酸
EP2346807A1 (en) 2008-11-17 2011-07-27 F. Hoffmann-La Roche AG Naphthylacetic acids
JP5373104B2 (ja) * 2008-11-17 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｔｈ２アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
CN103763924B (zh) * 2011-06-17 2016-05-18 默沙东公司 作为crth2受体调节剂的环烷基稠合的四氢喹啉
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US8691993B2 (en) * 2011-12-12 2014-04-08 Hoffmann-La Roche Inc. Piperidinyl naphthylacetic acids
BR112014014558A8 (pt) 2011-12-16 2017-07-04 Atopix Therapeutics Ltd composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
RU2014129613A (ru) 2011-12-21 2016-02-10 Актелион Фармасьютиклз Лтд Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2
CA2873097A1 (en) * 2012-05-11 2013-11-14 Todd M. Hansen Pyridazine and pyridine derivatives as nampt inhibitors
MX2014013758A (es) * 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
US9296723B2 (en) 2012-05-11 2016-03-29 Abbvie Inc. NAMPT inhibitors
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
MX370535B (es) 2013-11-18 2019-12-17 Forma Therapeutics Inc Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer.
US9727784B2 (en) * 2014-06-03 2017-08-08 Digitalglobe, Inc. Some automated and semi-automated tools for linear feature extraction in two and three dimensions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
EP0602209A1 (en) 1992-07-02 1994-06-22 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
EP1100495A4 (en) 1998-07-28 2002-09-25 Smithkline Beecham Corp PROPENAMIDES AS CCR5 MODULATORS
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6048873A (en) * 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
WO2001027086A1 (fr) 1999-10-14 2001-04-19 Kaken Pharmaceutical Co., Ltd. Derives de tetrahydroquinoline
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
JP2003519221A (ja) 2000-01-03 2003-06-17 ファルマシア コーポレイション シクロオキシゲナーゼ−２−媒介障害を治療するためのジヒドロベンゾピラン、ジヒドロベンゾチオピラン及びテトラヒドロキノリン
DE10005302A1 (de) 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
EP1283055A4 (en) 2000-04-07 2003-05-07 Takeda Chemical Industries Ltd SOLUBLE SECRETION PROMOTERS OF THE BETA-AMYOID PROTEIN PRECURSOR
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP2002053557A (ja) 2000-08-14 2002-02-19 Japan Tobacco Inc アポリポ蛋白ａ−ｉ産生促進薬
ES2256288T3 (es) 2000-08-29 2006-07-16 Allergan, Inc. Compuestos con actividad como inhibidores de citocromo p450rai.
US6291677B1 (en) * 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
AU2001286243A1 (en) 2000-09-14 2002-03-26 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
DE10103657A1 (de) 2001-01-27 2002-08-01 Henkel Kgaa Neue Kupplerkomponente für Oxidationsmittel
SE0101161D0 (sv) 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
BR0209238A (pt) 2001-04-30 2004-06-15 Pfizer Prod Inc Compostos úteis como intermediários
EP1505061A4 (en) 2002-05-16 2007-08-22 Shionogi & Co CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
JPWO2003097042A1 (ja) 2002-05-16 2005-09-15 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗剤
US20050228016A1 (en) 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
EP1556356B1 (en) * 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
JPWO2004052863A1 (ja) 2002-12-06 2006-04-13 協和醗酵工業株式会社 抗炎症剤
EP1435356A1 (en) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
EA200501376A1 (ru) * 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
MXPA06011540A (es) 2004-04-07 2007-01-26 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.

Also Published As

Publication number Publication date
SV2007002429A (es) 2007-02-19
DOP2006000054A (es) 2006-08-31
RU2007135224A (ru) 2009-03-27
CR9378A (es) 2008-01-21
US7951950B2 (en) 2011-05-31
WO2006091674A1 (en) 2006-08-31
BRPI0608553A2 (pt) 2010-01-12
NI200700221A (es) 2008-05-09
EP1861372A1 (en) 2007-12-05
UA90706C2 (ru) 2010-05-25
UY29397A1 (es) 2006-10-02
MA29330B1 (fr) 2008-03-03
CN101146776A (zh) 2008-03-19
GT200600093A (es) 2006-10-19
ZA200707498B (en) 2008-11-26
TW200640869A (en) 2006-12-01
IL185422A0 (en) 2008-01-06
KR20070114762A (ko) 2007-12-04
CA2598133A1 (en) 2006-08-31
TNSN07325A1 (en) 2008-12-31
MX2007010215A (es) 2007-11-07
AR052580A1 (es) 2007-03-21
US20060241109A1 (en) 2006-10-26
AU2006216713A1 (en) 2006-08-31
JP2008543726A (ja) 2008-12-04
NO20074388L (no) 2007-11-20

Similar Documents

Publication Publication Date Title
PE20061013A1 (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
PE20061348A1 (es) DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
AR078944A1 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
ES2655091T3 (es) Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20120399A1 (es) Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
RU2006137272A (ru) Производные 2-фенилпропионовой кислоты и содержащие их фармацевтические композиции
PE20060931A1 (es) Derivados de sulfonamida como moduladores de los receptores de glucocorticoides (gr)
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a
RU2008127445A (ru) Бициклические гетероциклические соединения в качестве противовоспалительных или антиаллергических агентов
PE20121085A1 (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9 (10)-dien-11-arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades
PE20080378A1 (es) Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa
AR072189A1 (es) Derivados heterociclicos de benzo[b][1,4] oxazinonas moduladores de adrenoreceptores beta 2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de enfermedades del aparato respiratorio.

Legal Events

Date Code Title Description
FC Refusal